+ Filter
Loading...
Custom Services order now ship next day

Anti-TNFRSF13C Recombinant Antibody Products

Anti-TNFRSF13C Recombinant Antibody Products

More Infomation

Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

More Infomation

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

For Research Use Only. Not For Clinical Use.


Creative Biolabs supplies a comprehensive range of anti-TNFRSF13C recombinant antibody products for customers worldwide and provides extensive assistance throughout the research process from experimental design to troubleshooting challenges. We prioritize your research success by providing timely answers to questions regarding product application, storage, and handling. In addition, we offer vital validation data and personalized protocols, equipping researchers with the tools needed for reliable and reproducible results.

BAFF Receptor: A Promising Target for Autoimmunity and B Cell Malignancy

The BAFF-receptor (BAFFR), encoded by the TNFRSF13C gene, is crucial for B cell survival, influencing protein synthesis and energy metabolism. The binding of BAFF to BAFFR activates pathways essential for the longevity of various B cell stages, from immature to mature cells. Research indicates that BAFF–BAFFR interaction is also vital for the persistence of memory B cells, autoimmune B cells, and malignant chronic lymphocytic leukemia (CLL) cells. Consequently, BAFF–BAFFR signaling significantly impacts immune responses and pathological conditions like autoimmunity and B-cell malignancies, making BAFFR a promising target for therapeutic strategies in these diseases.

Alternative Names

B-Cell-Activating Factor Receptor; Tumor Necrosis Factor Receptor Superfamily, Member 13C; BAFF-R; CD268 Antigen; Prolixin; BAFF Receptor; TNFRSF13C; CD268; Tumor Necrosis Factor Receptor Superfamily; BLyS Receptor 3; BR3

Background

B cell-activating factor (BAFF) enhances B-cell survival in vitro and is a regulator of the peripheral B-cell population. Overexpression of Baff in mice results in mature B-cell hyperplasia and symptoms of systemic lupus erythematosus (SLE). Also, some SLE patients have increased levels of BAFF in serum. Therefore, it has been proposed that abnormally high levels of BAFF may contribute to the pathogenesis of autoimmune diseases by enhancing the survival of autoreactive B cells. The protein encoded by this gene is a receptor for BAFF and is a type III transmembrane protein containing a single extracellular cysteine-rich domain. It is thought that this receptor is the principal receptor required for BAFF-mediated mature B-cell survival.

Anti-TNFRSF13C rAb Products

Our line of anti-TNFRSF13C recombinant antibody products offers versatile formulations and conjugation possibilities to meet various experimental requirements. This includes monoclonal and polyclonal antibodies, antibody-drug conjugates (ADCs), and recombinant antibody fragments. Designed to boost efficacy and accuracy, these antibodies are invaluable tools for exploring TNFRSF13C’s role in autoimmunity and B cell malignancy and for developing targeted therapies. Below is a curated list of antibodies that successfully inhibit TNFRSF13C.

Table 1. Featured anti-TNFRSF13C recombinant antibody products at Creative Biolabs.

Cat. No. Product Name Target Species Host Species Applications
MOR-3611 Rabbit Anti-TNFRSF13C Recombinant Antibody (clone DS3611AB) Human Rabbit IgG IHC-P, ICC, IF
MOB-1119z Mouse Anti-TNFRSF13C Recombinant Antibody (clone 11G12) Human Mouse IgG1 FC, IHC
MOB-0886MZ Recombinant Mouse Anti-Human TNFRSF13C Antibody (clone 22D2) Human Mouse antibody FC, IHC-P
HPAB-0741-CN Human Anti-TNFRSF13C Recombinant Antibody Human, Cynomolgus Human IgG2 ELISA, FC, Neut
HPAB-AP472-YC Human Anti-TNFRSF13C Recombinant Antibody Human Human IgG1, κ ELISA

Creative Quality Control

At Creative Biolabs, we provide top-tier TNFRSF13C recombinant antibodies renowned for their stringent quality assurance and reliability. Our comprehensive quality assurance protocols guarantee that every product adheres to the highest benchmarks, providing outstanding reliability for scientists and medical professionals engaged in immunotherapy and cancer studies.

Customer Reviews

Excellent
Ed***a
Human Anti-TNFRSF13C Recombinant Antibody (clone CB3s) (PABZ-123) (CAT#: PABZ-123)
I acquired the Human Anti-TNFRSF13C Recombinant Antibody (clone CB3s) for my cancer immunotherapy experiments and was thoroughly impressed with its performance. This antibody delivered outstanding specificity and sensitivity in my ELISA tests, enabling precise measurement of TNFRSF13C in various samples. The inclusive data sheet provided detailed instructions and suggested optimal conditions, which greatly facilitated my work. Overall, it was a highly satisfactory experience.
23/Nov/2021
Excellent
Vi***r
Rabbit Anti-TNFRSF13C Recombinant Antibody (clone DS3611AB) (CAT#: MOR-3611)
For my recent flow cytometry experiments aimed at analyzing immune cell populations, I utilized the Human Anti-TNFRSF13C Recombinant Antibody from Creative Biolabs. I was highly impressed with the antibody’s high binding affinity and specificity, which facilitated the accurate identification and quantification of TNFRSF13C-expressing cells. The antibody product was reliable and consistent, significantly contributing to the success of my study.
21/Mar/2022
Excellent
Mo***i
Human Anti-TNFRSF13C Recombinant Antibody (HPAB-0741-CN) (CAT#: HPAB-0741-CN)
I’ve utilized the Human Anti-TNFRSF13C Recombinant Antibody in my ELISA assays and am extremely satisfied with the results. The antibody provided exceptional specificity and sensitivity, enabling accurate measurement of TNFRSF13C levels in my samples. The product quality is outstanding, and it significantly contributed to the reliability of my research data. Highly recommended for anyone working in the field of immunotherapy and cancer research.
15/Jul2023

rAb Production

Our cutting-edge production platform for anti-TNFRSF13C recombinant antibodies utilizes genetically engineered cells to accurately produce and secrete antibodies targeting the TNFRSF13C protein. This method facilitates the scalable and cost-effective production of superior-quality antibodies.

Featured Anti-TNFRSF13C Recombinant Antibody Production PlatformsFig.1 Milligram-scale. (Creative Biolabs Original)
Fig.1 Milligram-scale anti-TNFRSF13C recombinant antibody production.

Fig.2 Gram-scale. (Creative Biolabs Original)Fig.2 Gram-scale anti-TNFRSF13C recombinant antibody production.

rAb Modalities

At Creative Biolabs, we are committed to providing an extensive selection of superior anti-TNFRSF13C recombinant antibodies in multiple formats, empowering researchers with cutting-edge tools for their scientific inquiries.

Fig.3 TNFRSF13C antibody production and modalities. (Creative Biolabs Original)Fig.3 Full-length anti-TNFRSF13C recombinant antibody production and modalities.

TNFRSF13C-Targeted Drug Information

Table 2. Public drug targeting TNFRSF13C.

Highest Phase Mechanism of Action Product Category Condition Organization
Phase III Anti-TNFRSF13C (Tumor Necrosis Factor Receptor Superfamily Member 13C; CD268; BAFF-R) Cancer Immunotherapy
Human Monoclonal Antibodies
Chronic lymphocytic leukemia
Hepatitis, autoimmune
Hidradenitis suppurativa
Idiopathic pulmonary fibrosis
Inflammatory disorders
Leukemia
Multiple sclerosis, relapsing-remitting
Nephritis, lupus
Pemphigus vulgaris
Rheumatoid arthritis
Scleroderma, diffuse
Sjogren syndrome
Systemic lupus erythematosus
Thrombocytopenia, immune (Purpura, idiopathic thrombocytopenic)
Warm antibody autoimmune hemolytic anemia (WAIHA)
MorphoSys
Novartis (Originator)
Phase I Anti-TNFRSF13C (Tumor Necrosis Factor Receptor Superfamily Member 13C; CD268; BAFF-R) Cancer Immunotherapy
Monoclonal Antibodies
Lymphoma, B-cell Shanghai Escugen Biotechnology (Originator)
Phase I Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 13C (TNFRSF13C; CD268; BAFF-R) Cancer Immunotherapy
Chimeric Antigen Receptor-Modified T Cells (CAR T Cells)
Hematologic-blood cancer Mayo Clinic (Originator)
Phase I Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 13B (TNFRSF13B, TACI)
Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 13C (TNFRSF13C; CD268; BAFF-R)
Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 17 (TNFRSF17, BCMA, CD269)
Signal Transduction Modulators
Cancer Immunotherapy
Chimeric Antigen Receptor-Modified T Cells (CAR T Cells)
Lymphoma, mantle cell
Multiple myeloma
Non-Hodgkin lymphoma
Sjogren syndrome
Case Western Reserve University (Originator)
Luminary Therapeutics (Originator)
Phase I Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 13C (TNFRSF13C; CD268; BAFF-R) Cancer Immunotherapy
Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) (Second-Generation CAR)
B-cell acute lymphocytic leukemia
Cancer
Lymphoma, B-cell
City of Hope (Originator)
City of Hope National Medical Center (City of Hope)
PeproMene Bio
University of Texas System (Originator)
Phase I Fc Fusion Proteins
Polypeptides, from 41 AA
Rheumatoid arthritis Biogen (Originator)
Genentech (Originator)
Roche
Preclinical Anti-CLEC4C (C-Type Lectin Domain Family 4 Member C; BDCA2)
Drugs Targeting Tumor Necrosis Factor Ligand Superfamily Member 13 (TNFSF13; APRIL)
Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 13C (TNFRSF13C; CD268; BAFF-R)
Fusion Proteins
Humanized Monoclonal Antibodies
Polypeptides, from 41 AA
Autoimmune disease Nanjing Leads Biolabs (Originator)
Preclinical Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 13C (TNFRSF13C; CD268; BAFF-R) Cancer Immunotherapy
Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) (Second-Generation CAR)
Lymphoma, mantle cell University of Oxford (Originator)
Preclinical Drugs Targeting B-Lymphocyte Antigen CD19
Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 13C (TNFRSF13C; CD268; BAFF-R)
Cancer Immunotherapy
Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) (Second-Generation CAR)
Acute lymphocytic leukemia Beckman Research Institute City of Hope (Originator)
Preclinical Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 13B (TNFRSF13B, TACI)
Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 13C (TNFRSF13C; CD268; BAFF-R)
Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 17 (TNFRSF17, BCMA, CD269)
Cancer Immunotherapy
Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) (Second-Generation CAR)
Cancer Case Western Reserve University (Originator)

(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)

Creative Biolabs provides a wide array of high-quality anti-TNFRSF13C recombinant antibodies, customized to suit diverse research needs. From high-throughput production to bespoke smaller-scale projects, our expert team guarantees the highest quality products, prompt delivery, and outstanding customer service. Contact us today to discover more about our anti-TNFRSF13C antibodies and the ways we can assist your research efforts.

  • 0
  • 0
Cart
    Go to compare

    Go to compare